Northern Trust’s Atara Biotherapeutics ATRA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $190K | Buy |
16,591
+4,251
| +34% | +$33.9K | ﹤0.01% | 3951 |
|
|
2026
Q1 | $58.4K | Hold |
12,340
| – | – | ﹤0.01% | 4219 |
|
|
2025
Q4 | $223K | Buy |
12,340
+1,307
| +12% | +$19.5K | ﹤0.01% | 3944 |
|
|
2025
Q3 | $158K | Sell |
11,033
-137
| -1% | -$1.58K | ﹤0.01% | 4043 |
|
|
2025
Q2 | $86.2K | Hold |
11,170
| – | – | ﹤0.01% | 4138 |
|
|
2025
Q1 | $66.3K | Hold |
11,170
| – | – | ﹤0.01% | 4192 |
|
|
2024
Q4 | $149K | Buy |
+11,170
| New | +$118K | ﹤0.01% | 4072 |
|
|
2024
Q3 | – | Sell |
-31,492
| Closed | -$268K | – | 4415 |
|
|
2024
Q2 | $268K | Sell |
31,492
-2,541
| -7% | -$38.2K | ﹤0.01% | 3752 |
|
|
2024
Q1 | $590K | Buy |
34,033
+216
| +0.6% | +$3.84K | ﹤0.01% | 3511 |
|
|
2023
Q4 | $434K | Buy |
33,817
+1,860
| +6% | +$43.4K | ﹤0.01% | 3583 |
|
|
2023
Q3 | $1.18M | Buy |
31,957
+147
| +0.5% | +$6.54K | ﹤0.01% | 3227 |
|
|
2023
Q2 | $1.28M | Sell |
31,810
-3,265
| -9% | -$185K | ﹤0.01% | 3253 |
|
|
2023
Q1 | $2.54M | Sell |
35,075
-161
| -0.5% | -$15.6K | ﹤0.01% | 2833 |
|
|
2022
Q4 | $2.89M | Buy |
35,236
+1,024
| +3% | +$107K | ﹤0.01% | 2797 |
|
|
2022
Q3 | $3.23M | Sell |
34,212
-508
| -1% | -$57.1K | ﹤0.01% | 2749 |
|
|
2022
Q2 | $6.76M | Buy |
34,720
+1,442
| +4% | +$235K | ﹤0.01% | 2309 |
|
|
2022
Q1 | $7.73M | Sell |
33,278
-1,132
| -3% | -$360K | ﹤0.01% | 2311 |
|
|
2021
Q4 | $13.6M | Buy |
34,410
+680
| +2% | +$286K | ﹤0.01% | 2036 |
|
|
2021
Q3 | $15.1M | Sell |
33,730
-1,142
| -3% | -$409K | ﹤0.01% | 1994 |
|
|
2021
Q2 | $13.6M | Sell |
34,872
-1,013
| -3% | -$361K | ﹤0.01% | 2169 |
|
|
2021
Q1 | $12.9M | Sell |
35,885
-515
| -1% | -$228K | ﹤0.01% | 2133 |
|
|
2020
Q4 | $17.9M | Buy |
36,400
+496
| +1% | +$229K | ﹤0.01% | 1865 |
|
|
2020
Q3 | $11.6M | Buy |
35,904
+4,757
| +15% | +$1.62M | ﹤0.01% | 2023 |
|
|
2020
Q2 | $11.3M | Buy |
31,147
+3,387
| +12% | +$856K | ﹤0.01% | 2022 |
|
|
2020
Q1 | $5.91M | Buy |
27,760
+837
| +3% | +$266K | ﹤0.01% | 2200 |
|
|
2019
Q4 | $11.1M | Buy |
26,923
+1,007
| +4% | +$347K | ﹤0.01% | 2110 |
|
|
2019
Q3 | $9.15M | Buy |
25,916
+5,307
| +26% | +$1.98M | ﹤0.01% | 2204 |
|
|
2019
Q2 | $10.4M | Sell |
20,609
-414
| -2% | -$292K | ﹤0.01% | 2132 |
|
|
2019
Q1 | $20.9M | Buy |
21,023
+151
| +0.7% | +$140K | 0.01% | 1647 |
|
|
2018
Q4 | $18.1M | Sell |
20,872
-91
| -0.4% | -$84.5K | 0.01% | 1665 |
|
|
2018
Q3 | $21.7M | Buy |
20,963
+1,068
| +5% | +$1.04M | 0.01% | 1735 |
|
|
2018
Q2 | $18.3M | Buy |
19,895
+4,238
| +27% | +$4.55M | ﹤0.01% | 1852 |
|
|
2018
Q1 | $15.3M | Buy |
15,657
+4,106
| +36% | +$3.74M | ﹤0.01% | 1891 |
|
|
2017
Q4 | $5.23M | Buy |
11,551
+72
| +0.6% | +$26.6K | ﹤0.01% | 2575 |
|
|
2017
Q3 | $4.75M | Sell |
11,479
-471
| -4% | -$178K | ﹤0.01% | 2664 |
|
|
2017
Q2 | $4.18M | Buy |
11,950
+1,283
| +12% | +$494K | ﹤0.01% | 2731 |
|
|
2017
Q1 | $5.48M | Buy |
10,667
+271
| +3% | +$112K | ﹤0.01% | 2507 |
|
|
2016
Q4 | $3.69M | Buy |
10,396
+346
| +3% | +$147K | ﹤0.01% | 2750 |
|
|
2016
Q3 | $5.37M | Buy |
10,050
+421
| +4% | +$229K | ﹤0.01% | 2476 |
|
|
2016
Q2 | $5.42M | Buy |
9,629
+2,051
| +27% | +$984K | ﹤0.01% | 2398 |
|
|
2016
Q1 | $3.6M | Buy |
7,578
+95
| +1% | +$42.8K | ﹤0.01% | 2622 |
|
|
2015
Q4 | $4.94M | Buy |
7,483
+174
| +2% | +$132K | ﹤0.01% | 2471 |
|
|
2015
Q3 | $5.75M | Buy |
7,309
+3,934
| +117% | +$4.8M | ﹤0.01% | 2354 |
|
|
2015
Q2 | $4.45M | Buy |
3,375
+579
| +21% | +$664K | ﹤0.01% | 2596 |
|
|
2015
Q1 | $2.91M | Buy |
2,796
+473
| +20% | +$313K | ﹤0.01% | 2870 |
|
|
2014
Q4 | $1.55M | Buy |
+2,323
| New | +$1.42M | ﹤0.01% | 3241 |
|
Other funds holding ATRA
VCM
SCA
VFT
Northern Trust's ATRA Position: Q2 2026 in Review
Northern Trust increased its Atara Biotherapeutics (ATRA) stake by 34% in Q2 2026, buying an estimated $33.9K and bringing the position to 16,591 shares worth $190K. The position accounts for ﹤0.01% of the portfolio, ranked #3951.
Northern Trust first reported a position in ATRA in Q4 2014 and has held it in 46 quarters since. The position peaked at $21.7M in Q3 2018. 21 funds tracked by Wall St. Rank hold ATRA as of Q2 2026.
- Northern Trust held 16,591 shares of Atara Biotherapeutics worth $190K as of Q2 2026.
- Northern Trust bought 4,251 Atara Biotherapeutics shares in Q2 2026, an estimated $33.9K.
- Atara Biotherapeutics made up ﹤0.01% of Northern Trust's portfolio in Q2 2026, its #3951 holding.
- Northern Trust first reported a position in Atara Biotherapeutics in Q4 2014 and has held it in 46 quarters since.
- Northern Trust's Atara Biotherapeutics position peaked at $21.7M in Q3 2018.
- 21 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q2 2026.
Based on Northern Trust's 13F filing for Q2 2026, filed 13 Aug 2026.